REGENXBIO Inc. and Nippon Shinyaku Co., Ltd. announced a strategic partnership to advance the development and commercialization of RGX-12 and RGX-111. These therapies target Mucopolysaccharidosis II (MPS II) for Hunter syndrome and Mucopolysaccharidosis I (MPS I) Hurler syndrome. Nippon Shinyaku to Lead Commercialization While REGENXBIO Retains Full Rights to PRV for Gene Therapies  As part … $810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.